Dr Dremencov completed his bachelor studies (BSc) in biology (1996) and master studies (MMedSc) in basic medical sciences (2000) in the Hebrew University of Jerusalem. He performed his doctoral studies in the Faculty of Life Sciences of Bar-Ilan University (Ramat-Gan, Israel; 2000-2004) and two postdoctoral fellowships in the Departments of Affective Disorders (2004-2006) and Translational Neuroscience (2007-2008) of the University of Ottawa Institute of Mental Health Research (Ontario, Canada). After working for five years in the private commercial sector (as a trial manager in Brains On-Line BV, a contract research organization, and CEO of Neuroken Consulting, a research and development consulting firm; both based in Groningen, the Netherlands), Dr Dremencov returned to the public academic sector after being appointed as a senior scientist in the Institutes of Molecular Physiology and Genetics and Experimental Endocrinology of the Slovak Academy of Sciences in Bratislava (maintaining his position of CEO of Neuroken Consulting). He has acted as an expert advisor to the Medical Research Council of the UK, EU FP7 Program, National Research Agency of France, US Department of Health and Human Services, and Ministry of Science and Education of the Russian Federation. Dr Dremencov is a member or editorial boards of several international journals (General Physiology and Biophysics, World Journal of Pharmacology, World Journal of Psychiatry, and World Journal of Neurology).
Research Interests: Eliyahu Dremencov, MMedSc, PhD, is a biological psychiatrist, neuropharmacologist and neurophysiologist. His primary scientific interests are pathophysiology and treatment of depression and related mood and anxiety disorders. Dr Dremencov investigates the role of interactions between brain monoamines (serotonin, norepinephrine, dopamine, and histamine) and neuropeptides (β-endorphin, neuropeptide-Y, oxytocin and vasopressin) in the response to antidepressant and antipsychotic drugs. He uses advanced in vivo research techniques in animal models (behavioral neuroscience, microdialysis, and electrophysiology) to investigate the mechanism of action of novel CNS drugs and to predict their clinical efficacy. Recently, Dr Dremencov expanded his research interests to the mechanism of beneficial mood effects of physical exercise and to the prenatal effects of stress and antidepressant drugs on brain development and functioning.